We’re excited to announce that we’ll be attending the 10th Annual Frontiers in Therapeutics and Diagnostics (FTD) Forum, hosted by SABPA. The conference will cover the transformative role of AI across drug discovery, advanced therapeutics, and precision diagnostics. Join us for a day of insightful presentations, expert perspectives, and productive conversations!
What is SABPA?
The SoCal Association for Biomedical and Pharmaceutical Advancements (SABPA) is a 501(c)(3) nonprofit organization, established in 2002 by professionals and scholars from the Chinese community in San Diego. By 2005, SABPA had expanded its presence to Orange County and Los Angeles. Today, the organization boasts over 3,500 members and subscribers, including scholars, professionals, and entrepreneurs in Southern California's biotech and pharmaceutical industries.
Event Overview
Date: April 17th, 2026
Venue: Hilton San Diego/Del Mar, 15575 Jimmy Durante Blvd, Del Mar, CA 92014
Event Schedule
For more information, please refer to the SABPA website.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in San Diego, California!
